Clinical Trials Logo

Hormone Refractory clinical trials

View clinical trials related to Hormone Refractory.

Filter by:
  • None
  • Page 1

NCT ID: NCT00550810 Active, not recruiting - Prostate Cancer Clinical Trials

Sutent Maintenance After Response to Taxotere

SMART
Start date: October 2007
Phase: Phase 2
Study type: Interventional

The major goal is to determine whether the experimental agent has clinically promising activity that would merit progression to a formal phase III trial. Patients with hormone refractory prostate cancer after docetaxel chemotherapy have limited treatment options and no systemic treatment has been proven to be effective. Because of its action, safety and simple administration SU011248 has potential for effectiveness in this disease setting. Promising activity in this study would provide the necessary proof-of-principle for a larger confirmatory study in this population, and potentially in earlier stages of this common disease.

NCT ID: NCT00498797 Completed - Prostate Cancer Clinical Trials

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.